首页> 外文期刊>Endocrine >Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy
【24h】

Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy

机译:胃肠胰腺神经内分泌肿瘤:在诊断和治疗中的新见解

获取原文
获取原文并翻译 | 示例
       

摘要

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare and heterogenous malignancies. Recent advances in histopathological classification according to the anatomical site of origin, proliferation rate, and extend of the disease have created a valid and powerful tool for the prognostic stratification of GEP-NETs. Chromogranin A is still the best available marker used for the biochemical confirmation of these tumors, but new more sensitive markers are urgently required. Although scintigraphy with 111In-octreotide has widely been applied for the localization and staging of GEP-NETs, newer imaging modalities based on the functional characteristics of these tumors are evolving aiming not only to facilitate the diagnosis but also prognosis and evaluation of treatment. Somatostatin receptors are the primary therapeutic targets through somatostatin analogs and peptide receptor radionuclide therapy (PRRT) producing symptomatic, biochemical and to a lesser extent antiproliferative effects. Due to the relatively limited and erratic response to chemotherapy, new molecular targeted therapies exploiting some of the biological properties of GEP-NETs such as increased vascularity and inhibition of pathways involved in downstream signal transduction have evolved. Some of these therapies, the mTOR inhibitor everolimus and the tyrosine kinase inhibitor sunitinib, have been recently validated in phase III studies producing practice changing outcomes. In addition, two oral chemotherapeutic agents temozolomide and capecitabine, show promising effects and may replace streptozotocin-based regimens whereas combination therapies with the angiogenesis inhibitor bevacizumab are being investigated. Although progression free survival is used as a feasible primary end point due to the long survival of patients even in the presence of extensive disease prolongation of overall survival following the introduction of new therapies needs to be established.
机译:胃肠道胰腺神经内分泌肿瘤(GEP-NETs)是相对罕见且异质的恶性肿瘤。根据解剖学起源,增殖率和疾病扩展的组织病理学分类的最新进展为GEP-NETs的预后分层创建了有效而强大的工具。嗜铬粒蛋白A仍然是用于这些肿瘤的生化确认的最佳可用标记,但是迫切需要新的更敏感的标记。尽管采用111 In-奥曲肽的闪烁显像术已广泛用于GEP-NET的定位和分期,但基于这些肿瘤功能特征的新型影像学方法正在发展,其目的不仅在于促进诊断,而且还包括预后和评估。治疗。生长抑素受体是通过生长抑素类似物和肽受体放射性核素治疗(PRRT)产生症状,生化和较小程度的抗增殖作用的主要治疗靶标。由于对化学疗法的响应相对有限且不稳定,因此已经开发出了利用GEP-NETs某些生物学特性(例如增加的血管性和抑制下游信号转导的途径)的新型分子靶向疗法。这些疗法中的一些疗法,即mTOR抑制剂依维莫司和酪氨酸激酶抑制剂舒尼替尼,最近在III期研究中得到了验证,从而产生了改变实践的结果。此外,两种口服化学治疗药物替莫唑胺和卡培他滨显示出有希望的效果,并可能取代基于链脲佐菌素的治疗方案,而正在研究将血管生成抑制剂贝伐单抗联合治疗。尽管由于患者的长期生存,无进展生存被用作可行的主要终点,即使在存在广泛疾病的情况下,也需要确定在引入新疗法后总体生存的延长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号